Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Stock Performance

Shares of PULM opened at $6.40 on Friday. The firm has a market cap of $23.37 million, a PE ratio of -2.42 and a beta of 1.54. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $8.44. The business’s 50 day moving average price is $4.69 and its two-hundred day moving average price is $2.98.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.